” U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC. The drug is for women whose ovarian cancer is associated with certain defective genes and whose cancer persists after multiple treatments.

Click here to read original article